Add Yahoo as a preferred source to see more of our stories on Google. A concert featuring a mix of classical, Broadway, jazz and pop songs is set for March 13 at the Rotch-Jones-Duff House & Garden ...

Moderna MRNA-1.55%decrease; red down pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part ...

Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50. Today they’ve nudged back to about $53 — but ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Moderna Stock Is Back on Investors’ Radar Moderna (MRNA) has reappeared on ...

Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, ...

Feb 19 (Reuters) - German biopharmaceutical company BioNTech (22UAy.DE), opens new tab sued Moderna (MRNA.O), opens new tab in Delaware federal court on Thursday, alleging that Moderna's COVID-19 shot ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology. By Christina Jewett and ...